Plasma Therapy Market Updates

Global Plasma Therapy Market size was valued at USD 310.0 million in 2023 and is poised to grow from USD 354.33 million in 2024 to USD 1032.23 million by 2032, growing at a CAGR of 14.3% during the forecast period (2025-2032). 

Global plasma therapy market's competitive landscape provides information by competitors. An overview of the company, financials, revenue, market potential, R&D investments, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launches, product breadth and depth, and application dominance are among the data that are included. Only the market emphasis on plasma therapy that the companies have is covered by the data points given above. 'CSL Behring (Australia) ', 'Grifols S.A. (Spain) ', 'Kedrion S.p.A. (Italy) ', 'Octapharma AG (Switzerland) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Zimmer Biomet (US) ', 'Baxter International Inc. (US) ', 'China Biologic Products Holdings, Inc. (China) ', 'GC Pharma (South Korea) ', 'Green Cross Corp. (South Korea) ', 'Japan Blood Products Organization (Japan) ', 'LFB SA (France) ', 'Shanghai RAAS Blood Products Co., Ltd. (China) ', 'China National Biotec Group Co., Ltd. (CNBG) (China) ', 'Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. (China) ', 'Jiangxi Boya Bio-Pharmaceutical Co., Ltd. (China) ', 'Bio Products Laboratory Ltd. (BPL) (UK) ', 'BioLife Plasma Services (US) ', 'Canadian Plasma Resources (Canada)'

The utilization of platelet-rich plasma is increasing as a result of increasing sports injury rates and an increase in cosmetic surgery, as well as growing participation in sporting activities. The rise of the industry is also driven by a increase in the use of platelet rich plasma (PRP) in research.

The rise in patients with androgenic alopecia and orthopedic disorders may present additional potential growth opportunities for the plasma therapy market in the coming years. However, the limited use of PRP in diabetic patients and kidney problems may pose further challenges to the growth of the market in the near future. The healthcare company's access to trying to cut treatment options - The number of available treatments has considerably risen as a result of the healthcare industry's continued advancement. This has aided the consumers in choosing a treatment choice that is appropriate for their level of disposable income. Numerous services offered by both the public and private sectors have also assisted the healthcare industry in improving its success rate, even with relation to rare disorders. The success rate for treating rare diseases has increased as a result of the faster progress being made in the field of healthcare technology and tools.

Due to the existence of top platelet-rich plasma therapy product manufacturers, active involvement of academic and research institutions in trying to cut research and development activities, rising public awareness of the benefits of platelet-rich plasma therapies, and support from regulatory bodies and the government to promote the use of PRP for medical purposes, North America held the largest market share for plasma therapy in 2021. The availability of highly skilled individuals and the region's well-developed healthcare infrastructure both drive market growth.